品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|---|
阿拉丁 | T108505-25g | 25g | 现货 | 504-17-6 |
2-硫代巴比妥酸 2-Thiobarbituric acid |
Moligand™, ≥98% |
|
|
阿拉丁 | T108505-100g | 100g | 现货 | 504-17-6 |
2-硫代巴比妥酸 2-Thiobarbituric acid |
Moligand™, ≥98% |
|
|
阿拉丁 | T108505-500g | 500g | 现货 | 504-17-6 |
2-硫代巴比妥酸 2-Thiobarbituric acid |
Moligand™, ≥98% |
|
|
阿拉丁 | T108505-5g | 5g | 现货 | 504-17-6 |
2-硫代巴比妥酸 2-Thiobarbituric acid |
Moligand™, ≥98% |
|
|
阿拉丁 | T108505-250g | 250g | 现货 | 504-17-6 |
2-硫代巴比妥酸 2-Thiobarbituric acid |
Moligand™, ≥98% |
|
|
阿拉丁 | T108505-2.5kg | 2.5kg | 现货 | 504-17-6 |
2-硫代巴比妥酸 2-Thiobarbituric acid |
Moligand™, ≥98% |
|
|
梯希爱 | T0192-25G | 25G | 现货 | 504-17-6 |
2-硫代巴比妥酸 2-Thiobarbituric Acid |
98.0% |
|
|
梯希爱 | T0192-100G | 100G | 现货 | 504-17-6 |
2-硫代巴比妥酸 2-Thiobarbituric Acid |
98.0% |
|
|
梯希爱 | T0192-500G | 500G | 现货 | 504-17-6 |
2-硫代巴比妥酸 2-Thiobarbituric Acid |
98.0% |
|
|
梯希爱 | T2834-5G | 5G | 现货 | 504-17-6 |
2-硫代巴比妥酸[用于生化研究] 2-Thiobarbituric Acid[for Bi... |
98.0% |
|
|
国药沪试 | 30178034 | 25g | 现货 | 504-17-6 |
2-硫代巴比妥酸 2-Thiobarbituric acid |
BR(沪试),≥98.5% |
|
|
阿法埃莎 | A12681-25g | 25g | 现货 | 504-17-6 |
4,6-二羟基-2-巯基嘧啶, 98% 4,6-Dihydroxy-2-mercaptopyri... |
98% |
|
|
阿法埃莎 | A12681-100g | 100g | 现货 | 504-17-6 |
4,6-二羟基-2-巯基嘧啶, 98% 4,6-Dihydroxy-2-mercaptopyri... |
98% |
|
|
阿法埃莎 | A12681-500g | 500g | 现货 | 504-17-6 |
4,6-二羟基-2-巯基嘧啶, 98% 4,6-Dihydroxy-2-mercaptopyri... |
98% |
|
|
阿法埃莎 | C11496-5GR | 5GR | 现货 | 504-17-6 |
4,6-二羟基-2-巯基嘧啶 4,6-Dihydroxy-2-mercaptopyri... |
|
|
|
阿法埃莎 | C11496-100GR | 100GR | 现货 | 504-17-6 |
4,6-二羟基-2-巯基嘧啶 4,6-Dihydroxy-2-mercaptopyri... |
|
|
|
阿法埃莎 | C11496-500GR | 500GR | 现货 | 504-17-6 |
4,6-二羟基-2-巯基嘧啶 4,6-Dihydroxy-2-mercaptopyri... |
|
|
|
毕得 | BD21058-100g | 100g | 现货 | 504-17-6 |
2-巯基-4,6-二羟基嘧啶 4,6-Dihydroxy-2-mercaptopyri... |
97% |
|
|
毕得 | BD21058-500g | 500g | 现货 | 504-17-6 |
2-巯基-4,6-二羟基嘧啶 4,6-Dihydroxy-2-mercaptopyri... |
97% |
|
|
毕得 | BD21058-10g | 10g | 现货 | 504-17-6 |
2-巯基-4,6-二羟基嘧啶 4,6-Dihydroxy-2-mercaptopyri... |
97% |
|
|